Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on proprietary enzymes and delivery technologies for injectable therapies. Based in San Diego, California, and founded in 1998, the company develops and commercializes products built around its patented recombinant human hyaluronidase enzyme, rHuPH20, which is designed to support the subcutaneous delivery of biologic drugs, other therapeutic molecules, small molecules, and fluids. Its portfolio includes Hylenex recombinant, XYOSTED, and a range of partnered or co-developed products such as Herceptin Hylecta, Phesgo, Mabthera SC, Tecentriq SC, Ocrevus SC, HYQVIA, DARZALEX, and several other injectable therapies. Halozyme also has collaboration and licensing agreements with multiple pharmaceutical companies, including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen Pharmaceuticals, Merus, and Skye Bioscience. The company operates in the United States and internationally.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HALO
|
$125.15
|
1.8% Upside
|
Fair
|
$108.89
|
-11.4% Downside
|
Fair
|
Great
|
0.0%
|
33.7x
|
97.2x
|
8.4x
|
13.945 B
|
15.903 B
|
12.8%
|
98.8%
|
9.0
|
194.9%
|
